Valneva Announces Start of Phase II Clinical Trial of its Clostridium difficile vaccine candidate
Valneva SE announced the initiation of the Phase II clinical trial of its VLA84 prophylactic vaccine candidate against Clostridium difficile (C. difficile), the main cause of nosocomial diarrhea. Data from the Phase I study in healthy elderly and adults showed good safety and immunogenicity of the vaccine candidate, and indicated functionality of induced antibodies, supporting the Company’s decision to progress the vaccine candidate into Phase II.
The Phase II study (VLA84-201) will enroll 500 healthy subjects aged 50 years and older. This age group represents the target population for a prophylactic C. difficile vaccine as the risk to contract the infection-associated disease increases with age. The randomized, placebo-controlled, observer-blind study will be conducted in Germany as well as in the United States under an Investigational New Drug application (IND). It aims to confirm the optimal dose and formulation of the vaccine in two different age groups and to generate sufficient additional clinical data to advance the program into Phase III.
Valneva expects to announce the first results of the Phase II study at the end of 2015.
Organizations
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents

SRI spins off AI-powered drug discovery platform Synfini, Inc. - Synfini to commercialize and scale automated compound testing for rapid drug production
Argonne, University of Chicago scientists develop targeted cancer treatment using nanomaterials - Nano-bio material kills cancer cells, leaves healthy cells in unharmed

Blood tests could predict survival odds for patients with metastatic cancer - By measuring the proportion of DNA in the bloodstream that comes from a tumor, liquid biopsies may be able to guide treatment discussions
Complex inhalers prevent patients from taking medicine

Bacterium from coal mine fire could aid drug targeting
What is a laboratory mouse? Jackson, UNC researchers reveal the details
Intercell announces initiation in the U.S. of a Phase III study for vaccine to protect children against Japanese Encephalitis
ScanBalt Campus - Coordinating Education and Research in ScanBalt BioRegion
Thermocouple
Zebrafish study reveals clues to healing spinal cord injuries
Alpha-ketoglutaric_acid
